<DOC>
	<DOCNO>NCT02630394</DOCNO>
	<brief_summary>Acute chest syndrome ( ACS ) , lung complication sickle cell disease ( SCD ) , second common cause hospitalization lead cause death SCD . ACS associate airway inflammation , major cause pulmonary infection atypical organism . To date , drug available reduce inflammation risk recurrent ACS . Macrolides group antibiotic exert immunomodulatory anti-inflammatory action vitro vivo . In addition , macrolides reduce bacterial burden airway atypical organism , play important role pathophysiology ACS . Numerous study evaluate macrolide prophylaxis condition associate lung inflammation , cystic fibrosis , asthma , bronchiectasis etc. , high quality evidence find macrolides beneficial disease modify agent lead improvement airway inflammation , reduce pulmonary exacerbation improve lung function . The investigator hypothesize azithromycin prophylaxis well tolerate potential reduce inflammation improve lung outcome child SCD history ACS . A prospective , single arm , open label feasibility study azithromycin prophylaxis perform child SCD history ACS specific aim examine feasibility , safety tolerability azithromycin prophylaxis administration participant SCD , examine whether azithromycin prophylaxis potential improve lung outcome . In addition , study determine whether azithromycin prophylaxis reduces inflammation participant SCD history ACS .</brief_summary>
	<brief_title>A Pilot Study Azithromycin Prophylaxis Acute Chest Syndrome Sickle Cell Disease</brief_title>
	<detailed_description>Specific Aims : Acute chest syndrome ( ACS ) , lung complication sickle cell disease ( SCD ) , second common cause hospitalization lead cause death SCD . Recurrent ACS associate poor lung function outcome comparable cystic fibrosis . ACS associate airway inflammation , major cause pulmonary infection atypical organism . To date , drug available reduce inflammation risk recurrent ACS . Thus new therapy urgently need address important issue associate increased morbidity debilitate chronic lung disease mortality SCD . Macrolides group antibiotic exert immunomodulatory anti-inflammatory action vitro vivo . It show inhibit neutrophil activation mobilization , modulate oxidant production neutrophil proinflammatory cytokine synthesis release leukocytes , reduce systemic marker inflammation , inhibit intercellular adhesion molecule epithelial cell surface , block activation certain nuclear transcription factor . In addition , macrolides reduce bacterial burden airway atypical organism , play important role pathophysiology ACS . Indeed , numerous study evaluate macrolide prophylaxis condition associate lung inflammation , cystic fibrosis , asthma , bronchiectasis etc. , high quality evidence find macrolides beneficial disease modify agent lead improvement airway inflammation , reduce pulmonary exacerbation improve lung function . However , azithromycin never study SCD . The investigator hypothesize azithromycin prophylaxis well tolerate potential reduce inflammation improve lung outcome child SCD history ACS . A prospective , single arm , open label feasibility study azithromycin prophylaxis perform child SCD history ACS follow specific aim : Specific Aim 1 : Examine feasibility , safety tolerability azithromycin prophylaxis administration child SCD . A cohort 15 participant sickle cell disease 6 16 year old place azithromycin prophylaxis , follow closely evaluate medication adherence adverse effect take medication . Specific Aim 2 : Examine whether azithromycin prophylaxis potential improve lung outcome participant SCD history ACS . In cohort 15 patient , baseline pulmonary function test perform evaluate Forced expiratory volume 1 sec ( FEV1 ) Forced vital capacity ( FVC ) measurement prior start azithromycin prophylaxis , study end period 1 year evaluate change . Specific Aim 3 : Determine whether azithromycin prophylaxis reduces inflammation participant SCD history ACS . In cohort 15 participant , baseline marker inflammation perform , specifically C-reactive protein ( CRP ) , Tumor necrosis factor Alpha ( TNF-α ) , interleukin IL-1 , IL-1β , IL-4 , IL-6 , IL-8 , repeat specific time interval 16 week , 32 week 48 week ( study end ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Acute Chest Syndrome</mesh_term>
	<criteria>Established diagnosis SCD ( Hemoglobin SS , hemoglobin Sβ0 thalassemia ) History acute chest syndrome history acute chest syndrome confirm retrospective medical chart review meet standard definition mention Background section . Age ≥ 6 year 16 year old Hemoglobin Sβ+thalassemia hemoglobin SC subject exclude group patient typically severe SCD place risk develop recurrent acute chest syndrome No history acute chest syndrome Significant neurologic impairment judge health care provider . Inability take/swallow tablet History poor adherence clinic visit . History renal hepatic dysfunction Chronic red blood cell transfusion History allergy azithromycin macrolide antibiotic History cardiac arrhythmia History prolong QT</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>acute chest syndrome</keyword>
</DOC>